BIOCOPY: the new biomolecule copying and screening solution for diagnostics and therapeutics

Projektinformationen

BIOCOPY

ID Finanzhilfevereinbarung: 816576

DOI

10.3030/816576

Projekt abgeschlossen

EK-Unterschriftsdatum 31 Mai 2018

Startdatum 1 Juni 2018

Enddatum 30 September 2018

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

BIOCOPY GMBH
Germany

Periodic Reporting for period 1 - BIOCOPY (BIOCOPY: the new biomolecule copying and screening solution for diagnostics and therapeutics)

Berichtszeitraum: 2018-06-01 bis 2018-09-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Biotechnology and molecular biology have helped to develop therapeutics and diagnostics products, and vaccines have been particularly relevant in human and animal health. However, their discovery and obtention take long times and have high costs, in part because of the inefficient selection and analysis of biomolecules. BioCopy is a German start-up with the goal of provide a unique patented technology for the copying and screening of biomolecules, which is analogous to a photocopier. We have developed a method to copy DNA into DNA/RNA or proteins and we offer as by-products our surfaces, a label-free analytics system and the copying of aptamers and phage/ribosome pools, but we want to focus in the identification of candidate proteins for the development of animal vaccines. We have preliminary developed and validated out technology and now we aim to technically optimize it and validate its use in veterinary vaccines discovery to enter the market successfully.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

At the technical level, we worked on defining the main needs to optimize, adapt and validate our whole system, and each one of its components and derived products to reach a TRL9. At the commercial level, we searched and identified many potential users and analyzed the advantages we can offer to them. We were also able to study different markets, compare our innovation with main competitors and describe BioCopy stakeholders, to evaluate the options we have to establish in the biopharma and animal vaccines markets as a highly competitive alternative. Financially, we could estimate the budget needed to reach commercialization and make projections on sells and profits after market launch.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Producing microarrays as BioCopy does would generate extremely high costs and times with current methods and in some cases it would be technologically impossible. None of the existing companies provides a similar tool for biomolecules copying and screening with the broad range of services and products we offer and with equivalent performance. Moreover, by using our system those companies can improve their processes and developmental pipelines and optimize results and costs. With our technology we can increase quantity and quality of biomolecules copied and analyzed by a minimum of 10-fold and significantly reduce costs.

Identification of vaccine candidates

Concept of the biomolecules copying

Company logo